Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China
ObjectiveThis study aimed to investigate the association between the utilization of Sodium-dependent glucose cotransporters inhibitors (SGLT2i) in real-world settings and kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) in mainland China.MethodsIn a retrospecti...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1468435/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846142996267925504 |
|---|---|
| author | Xiang Xiao Xiang Xiao Xiang Xiao Shuming Ji Tao Zheng Tianzhu Wang Dapeng Jiang Fang Liu Fang Liu |
| author_facet | Xiang Xiao Xiang Xiao Xiang Xiao Shuming Ji Tao Zheng Tianzhu Wang Dapeng Jiang Fang Liu Fang Liu |
| author_sort | Xiang Xiao |
| collection | DOAJ |
| description | ObjectiveThis study aimed to investigate the association between the utilization of Sodium-dependent glucose cotransporters inhibitors (SGLT2i) in real-world settings and kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) in mainland China.MethodsIn a retrospective analysis of electronic medical records from West China Hospital of Sichuan University, patients with T2D and CKD were included. Patients were divided into two groups, those initiating treatment with SGLT2i and those receiving other glucose-lowering drugs (oGLDs). The primary focus lies in examining the impact of SGLT2i on the decline slope of eGFR and major kidney events in these patients.ResultsWe enrolled 944 patients diagnosed with both T2D and CKD. Out of these, 605 patients were prescribed SGLT2i, while the remaining 339 patients received oGLDs. The median follow-up duration were 16.8 months and 20.6 months, respectively. Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m2 per year reduction compared to oGLDs, 95% CI: 4.73–5.15). A total of 101 kidney composite endpoint events occurred, with 31 events in the SGLT2i group and 70 events in the oGLDs group. The use of SGLT2i was associated with a 65% decrease in the risk of kidney composite endpoint events (hazard ratio 0.35, 95% CI 0.19–0.63).ConclusionsIn clinical practice, SGLT2i have shown favorable effects on kidney prognosis in patients with T2D and CKD in mainland China. These effects remain consistent across patients with varying risks of CKD progression.Clinical Trial Registration NumberChiCTR2300068497. |
| format | Article |
| id | doaj-art-5d17eb3eb35b4e4aa7451ed76a68cad4 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-5d17eb3eb35b4e4aa7451ed76a68cad42024-12-03T04:23:48ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-12-011510.3389/fphar.2024.14684351468435Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from ChinaXiang Xiao0Xiang Xiao1Xiang Xiao2Shuming Ji3Tao Zheng4Tianzhu Wang5Dapeng Jiang6Fang Liu7Fang Liu8Division of Nephrology, West China Hospital of Sichuan University, Chengdu, ChinaDepartment of Nephrology, The first affiliated hospital of Chengdu Medical college, Chengdu, ChinaLaboratory of Diabetic Kidney Disease, Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, ChinaDepartment of Project Design and Statistics, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, ChinaDivision of Nephrology, West China Hospital of Sichuan University, Chengdu, ChinaLaboratory of Diabetic Kidney Disease, Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, ChinaObjectiveThis study aimed to investigate the association between the utilization of Sodium-dependent glucose cotransporters inhibitors (SGLT2i) in real-world settings and kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) in mainland China.MethodsIn a retrospective analysis of electronic medical records from West China Hospital of Sichuan University, patients with T2D and CKD were included. Patients were divided into two groups, those initiating treatment with SGLT2i and those receiving other glucose-lowering drugs (oGLDs). The primary focus lies in examining the impact of SGLT2i on the decline slope of eGFR and major kidney events in these patients.ResultsWe enrolled 944 patients diagnosed with both T2D and CKD. Out of these, 605 patients were prescribed SGLT2i, while the remaining 339 patients received oGLDs. The median follow-up duration were 16.8 months and 20.6 months, respectively. Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m2 per year reduction compared to oGLDs, 95% CI: 4.73–5.15). A total of 101 kidney composite endpoint events occurred, with 31 events in the SGLT2i group and 70 events in the oGLDs group. The use of SGLT2i was associated with a 65% decrease in the risk of kidney composite endpoint events (hazard ratio 0.35, 95% CI 0.19–0.63).ConclusionsIn clinical practice, SGLT2i have shown favorable effects on kidney prognosis in patients with T2D and CKD in mainland China. These effects remain consistent across patients with varying risks of CKD progression.Clinical Trial Registration NumberChiCTR2300068497.https://www.frontiersin.org/articles/10.3389/fphar.2024.1468435/fulltype 2 diabetesdiabetic kidney diseasesodium-glucose transport protein 2 (SGLT2) inhibitorsreal world studyoutcomes |
| spellingShingle | Xiang Xiao Xiang Xiao Xiang Xiao Shuming Ji Tao Zheng Tianzhu Wang Dapeng Jiang Fang Liu Fang Liu Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China Frontiers in Pharmacology type 2 diabetes diabetic kidney disease sodium-glucose transport protein 2 (SGLT2) inhibitors real world study outcomes |
| title | Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China |
| title_full | Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China |
| title_fullStr | Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China |
| title_full_unstemmed | Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China |
| title_short | Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China |
| title_sort | kidney outcomes associated with sglt2 inhibitors compared to other glucose lowering drugs a real world study from china |
| topic | type 2 diabetes diabetic kidney disease sodium-glucose transport protein 2 (SGLT2) inhibitors real world study outcomes |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1468435/full |
| work_keys_str_mv | AT xiangxiao kidneyoutcomesassociatedwithsglt2inhibitorscomparedtootherglucoseloweringdrugsarealworldstudyfromchina AT xiangxiao kidneyoutcomesassociatedwithsglt2inhibitorscomparedtootherglucoseloweringdrugsarealworldstudyfromchina AT xiangxiao kidneyoutcomesassociatedwithsglt2inhibitorscomparedtootherglucoseloweringdrugsarealworldstudyfromchina AT shumingji kidneyoutcomesassociatedwithsglt2inhibitorscomparedtootherglucoseloweringdrugsarealworldstudyfromchina AT taozheng kidneyoutcomesassociatedwithsglt2inhibitorscomparedtootherglucoseloweringdrugsarealworldstudyfromchina AT tianzhuwang kidneyoutcomesassociatedwithsglt2inhibitorscomparedtootherglucoseloweringdrugsarealworldstudyfromchina AT dapengjiang kidneyoutcomesassociatedwithsglt2inhibitorscomparedtootherglucoseloweringdrugsarealworldstudyfromchina AT fangliu kidneyoutcomesassociatedwithsglt2inhibitorscomparedtootherglucoseloweringdrugsarealworldstudyfromchina AT fangliu kidneyoutcomesassociatedwithsglt2inhibitorscomparedtootherglucoseloweringdrugsarealworldstudyfromchina |